The Effects of Programmed Death-ligand 1 on Postoperative Pain for Lung Cancer Patients

Peking University

Status: Enrolling

Conditions: Postoperative Pain; Lung Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT06503432

2020PHB252-01

Details and patient eligibility

About

The concentration of plasma programmed death-ligand 1(PD-L1) for lung cancer patients before video-assisted thoracoscopic surgery is detected. According to the distribution of plasma concentration, patients are divided into high or low expression of PD-L1. Differences in acute and chronic postoperative pain are compared between two groups of patients. And effects of PD-L1 expresion on postoperative pain in lung cancer patients are explained.

Full description

Chronic pain after video-assisted thoracoscopic surgery (VATS) has been a major concern for lung cancer patients. The relationship between plasma programmed cell death ligand-1 (PD-L1) concentration and chronic pain in post-VATS is uncertain. This study aims to explore the effects of PD-L1 levels on chronic pain and provide proactive pain management regimen according to individual genetic differences.

The concentration of plasma PD-L1 for lung cancer patients before video-assisted thoracoscopic surgery is detected. According to the distribution of plasma concentration, patients are divided into high or low expression of PD-L1. Differences in acute and chronic postoperative pain are compared between two groups of patients. And effects of PD-L1 expresion on postoperative pain in lung cancer patients are explained.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. American Society of Anesthesiologists physical status I-IV (males and females).
2. 18-80 years of age.
3. Patients undergoing video-assisted thoracoscopic surgery for malignant lung disease.

Exclusion criteria

1. History of opioid abuse.
2. Known psychiatric disorders.
3. Unexpected conversion to thoracotomy or transferred to intensive care unit for further treatment.
4. Combined with other surgeries or sites.

Trial design

100 participants in 2 patient groups

high expression of programmed death-ligand 1

Description:

According to the distribution of PD-L1 concentration levels in the plasma, participants were divided into two groups: high expression of PD-L1 (PD-L1(H)) and low expression of PD-L1 (PD-L1(L)).

low expression of programmed death-ligand 1

Description:

According to the distribution of PD-L1 concentration levels in the plasma, participants were divided into two groups: high expression of PD-L1 (PD-L1(H)) and low expression of PD-L1 (PD-L1(L)).